Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Prognostic Gene Expression Profile Testing and SLNB Risk Prediction
Description
Dr. Doug Grossman, an expert in melanoma, discussed the role of prognostic gene expression profiling (GEP) in predicting melanoma behavior and risk of metastasis based on tumor gene expression. He highlighted several commercial GEP tests, including the DecisionDX-Melanoma, Melogenics, and Merlin tests, primarily used in the US and Europe for assessing melanoma risk. These tests provide binary results categorizing patients into low or high-risk classes and aim to inform clinical decisions, including the need for sentinel lymph node biopsy (SLNB) and adjuvant therapy. Although there are indications that the GEP tests can alter treatment management, significant concerns remain regarding clinical utility, especially the lack of evidence showing improved patient outcomes from using these tests. Current guidelines do not advocate for the routine use of GEP tests in melanoma management due to insufficient evidence and the potential for false positives in early stages. Moreover, while GEP tests might reduce unnecessary SLNB procedures, cost-effectiveness compared to medical nomograms that estimate positivity risk remains debated. There is a need for further research and clinical trials to clarify the value of GEP testing in managing melanoma.
View moreConclusions
- Prognostic gene expression profile (GEP) testing may predict melanoma behavior and risk of metastasis.
- The Decision Dx Melanoma (31-GEP) test shows significant predictive ability for distant metastasis-free survival.
- Class 1A of the 31-GEP test is associated with 100% melanoma-specific survival.
- Clinical utility of GEP testing remains uncertain due to lack of evidence on improving patient outcomes based on test results.
- The NCCN guidelines do not recommend the routine use of GEP tests for melanoma management, demanding more extensive studies.
- GEP tests may reduce unnecessary sentinel lymph node biopsies (SLNB) in patients identified as low-risk by these tests.
- Despite their limitations, GEP tests are increasingly used in clinical practice.
- There is a need for further research to identify which specific patient populations will benefit from GEP testing.
- The cost-effectiveness of GEP tests compared to traditional nomograms needs validation through clinical studies.
- Smith, Cancer Biol Ther 2005
- Haqq, PNAS 2005
- Jaeger, Clin Cancer Res 2007
- Gastman, JAAD 2019
- Jarrell, JAAD 2022
- Durgham, Cancers 2024
- Dillon, Current Med Res Opinion 2022
- Reschke, Eur J Cancers 2022
- Forchhammer, J Clin Oncol 2023
- Amaral, Eur J Cancer 2020
- Gambichler, J Cancer Res Clin Oncol 2022
- Fastner, Cancer Med 2023
- Vetto et al, (2019)
- Whitman et al, (2021)
- Kriza et al, (2019)
- Yamamoto et al, (2022)
- Guenther et al, (2024)
- Bellomo et al, (2020)
- Olofsson Bagge, Maddineni, Ann Surg Oncol 2024; Drebin, Ann Surg Oncol 2024
- NCCN Melanoma Version 1.2025 https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492